Arzu Mirza, Mehmet Cabalak, Ozgur Gunal, Aslıhan Candevir, Bircan Kayaaslan, İlkay Karaoglan, Hatun Öztürk Cerik, Deniz Ozer, İlknur Erdem, Tuba Damar Çakırca, Dilek Bulut, Seyma Topal, Ayse Seza İnal, Ayse Özlem Mete, Yasemin Cakır Kıymaz, Fatma Eser, Ceren Cesur, Ayhan Akbulut, Muhammed Bekcibası, İlknur Esen Yıldız, Mehmet Ali Asan, Pınar Cakmak
{"title":"Hepatitis B Vaccination Rates and Risk Factors Affecting Vaccine Response in People Living with HIV in Turkey.","authors":"Arzu Mirza, Mehmet Cabalak, Ozgur Gunal, Aslıhan Candevir, Bircan Kayaaslan, İlkay Karaoglan, Hatun Öztürk Cerik, Deniz Ozer, İlknur Erdem, Tuba Damar Çakırca, Dilek Bulut, Seyma Topal, Ayse Seza İnal, Ayse Özlem Mete, Yasemin Cakır Kıymaz, Fatma Eser, Ceren Cesur, Ayhan Akbulut, Muhammed Bekcibası, İlknur Esen Yıldız, Mehmet Ali Asan, Pınar Cakmak","doi":"10.2174/011570162X411549251129074829","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>HIV-HBV coinfection is common among individuals living with HIV; therefore, hepatitis B vaccination is recommended. However, vaccine response rates in people living with HIV are lower than those observed in the healthy population. The aim of this study was to determine HBV vaccination rates and identify risk factors affecting vaccine response in people living with HIV.</p><p><strong>Materials and methods: </strong>This multicenter, observational, retrospective study included patients over 18 years of age who were diagnosed with HIV infection and followed for at least six months between January 2018 and January 2024. Patients were screened for HBV using HBsAg, Anti- HBc IgG, and Anti-HBs serology, and Anti-HBs levels were measured at least 4-8 weeks after completion of the HBV vaccination schedule.</p><p><strong>Results: </strong>Of 811 people living with HIV, 274 met the inclusion criteria. The median age was 37.5 years (range: 18-75), and 85% were male. The hepatitis B vaccination rate in this cohort was 33.7%. Following the HBV vaccination schedule, vaccine response (Anti-HBs ≥10 IU/L) was observed in 73.4% of individuals. Hypertension and chronic obstructive pulmonary disease (COPD) were identified as independent risk factors affecting vaccine response (p = 0.016 and p = 0.026, respectively).</p><p><strong>Conclusion: </strong>Vaccine response was found to be lower in individuals with hypertension and COPD. These factors should be considered when administering the hepatitis B vaccine to people living with HIV to improve immunization outcomes.</p>","PeriodicalId":10911,"journal":{"name":"Current HIV Research","volume":" ","pages":"190-202"},"PeriodicalIF":0.8000,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current HIV Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/011570162X411549251129074829","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: HIV-HBV coinfection is common among individuals living with HIV; therefore, hepatitis B vaccination is recommended. However, vaccine response rates in people living with HIV are lower than those observed in the healthy population. The aim of this study was to determine HBV vaccination rates and identify risk factors affecting vaccine response in people living with HIV.
Materials and methods: This multicenter, observational, retrospective study included patients over 18 years of age who were diagnosed with HIV infection and followed for at least six months between January 2018 and January 2024. Patients were screened for HBV using HBsAg, Anti- HBc IgG, and Anti-HBs serology, and Anti-HBs levels were measured at least 4-8 weeks after completion of the HBV vaccination schedule.
Results: Of 811 people living with HIV, 274 met the inclusion criteria. The median age was 37.5 years (range: 18-75), and 85% were male. The hepatitis B vaccination rate in this cohort was 33.7%. Following the HBV vaccination schedule, vaccine response (Anti-HBs ≥10 IU/L) was observed in 73.4% of individuals. Hypertension and chronic obstructive pulmonary disease (COPD) were identified as independent risk factors affecting vaccine response (p = 0.016 and p = 0.026, respectively).
Conclusion: Vaccine response was found to be lower in individuals with hypertension and COPD. These factors should be considered when administering the hepatitis B vaccine to people living with HIV to improve immunization outcomes.
期刊介绍:
Current HIV Research covers all the latest and outstanding developments of HIV research by publishing original research, review articles and guest edited thematic issues. The novel pioneering work in the basic and clinical fields on all areas of HIV research covers: virus replication and gene expression, HIV assembly, virus-cell interaction, viral pathogenesis, epidemiology and transmission, anti-retroviral therapy and adherence, drug discovery, the latest developments in HIV/AIDS vaccines and animal models, mechanisms and interactions with AIDS related diseases, social and public health issues related to HIV disease, and prevention of viral infection. Periodically, the journal invites guest editors to devote an issue on a particular area of HIV research of great interest that increases our understanding of the virus and its complex interaction with the host.